Clinical Trials Logo

Discoid Lupus Erythematosus clinical trials

View clinical trials related to Discoid Lupus Erythematosus.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT03866317 Withdrawn - Clinical trials for Discoid Lupus Erythematosus

A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus

Start date: September 1, 2019
Phase: Phase 2
Study type: Interventional

Discoid lupus erythematosus is a chronic inflammatory skin condition and may lead to itch, skin pain, open sores, scarring, disfigurement and hair loss. Studies have shown that IL-17A may play a major role in inflammation and in the pathogenesis of discoid lupus. Treatment of discoid lupus sometimes is a challenge and unresponsive to current therapies. Secukinumab, an anti-IL-17A monoclonal antibody has been safe and effective in the treatment of psoriasis. The investigators propose to study the efficacy and safety of secukinumab in discoid lupus.